Campbell, James N
- Centrexion Therapeutics Corporation (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #1,759
- Top 10% Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$3.1M
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#1,759
By linked amount among FY2023 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Campbell, James N as a PI. Multi-PI records show the full award amount for context.
- 4UH3NS123965-02UH3Contact PINovel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain$3.1Maward amount
Award organization
Organizations that administered FY2023 awards listing Campbell, James N as a PI.
FY2023 award administered by Centrexion Therapeutics Corporation (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardCentrexion Therapeutics Corporation
- 2006$500K Cumulative Funding
- 2006Entered Top 50% NationallyRanked #6907
- 2007$1M Cumulative Funding
- 2021$2M Cumulative Funding
- 2021Entered Top 25% NationallyRanked #3304
- 2023$5M Cumulative Funding
- 2023Entered Top 10% NationallyRanked #1759